Drug intelligence / Profile preview

VT-101

Development stage: Unknown
Lead developer: Wanbang Biopharmaceuticals
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intravesical Instillation

Overview

VT-101 is a recombinant oncolytic adenovirus injection solution currently under investigation for the treatment of non-muscle invasive bladder cancer (NMIBC). It is administered via intravesical instillation and is designed to evaluate its efficacy and safety in patients with NMIBC. Oncolytic viruses selectively infect and replicate within cancer cells, leading to cell lysis and the release of tumor antigens, which can subsequently stimulate an anti-tumor immune response.

Other names: alpha-tocopheroloxyacetic acidalpha-TEAa-TEA-Lysinealpha-TEA-Lysine

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on VT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT-101.

Explore the full profile